Biocon Knocked Back By FDA On Human Insulin
Biosimilar Filing Receives CRL Citing Need For More Data And Facility Remediation
Biocon has seen its insulin-R application knocked back by the US FDA, with a complete response letter citing a need for more data as well as the need for remediation activities at its Bangalore facilities.
You may also be interested in...
Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
2022 Hires Reflect Global Challenges And Opportunities
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
Tambe Moves Up To Lead Biocon Biologics
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.